EACS2023: 682 Treatment outcomes among children and adolescents living with HIV (CALHIV) receiving 1,3,6 months ART refills: a program data review in Eastern Uganda B. Ainembabazi , R.N. Ssebunya , W. Akobye , P. Nahirya-Ntege , P. Elyanu , D. Kiragga Baylor College of Medicine Children's Foundation, Kampala, Uganda General data Abstract category: Access and delivery of care Abstract body Purpose: In 2022, Uganda’s ministry of Health recommended 6 monthly antiretroviral therapy (ART) refills for Children and adolescents living with HIV. Treatment outcomes among this population following this recommendation have not yet been documented. We aimed to determine viral load (VL) suppression and retention among CALHIV receiving 1, 3 and 6 monthly ART refills. Method: A cross sectional evaluation using data from electronic medical records in 118 health facilities was conducted. The most recent five clinic visits as of 15 May 2023 were considered. A most recent VL <1000 copies/ml was considered suppressed while a client was considered retained in care if they were within 28 days of their expected clinic visit date. Clients who received 30 days or less of ART on all the five clinic encounters were categorized as having received 1 month of drugs, those who received 180 days or more on any of the five clinic visits were considered as 6 months or more and the rest were considered to have received 2-5 months of drugs. Modified Poisson regression adjusting for clustering at facility level was used. Results: A total of 2659 records were abstracted. Compared to those who received 1 month of ART, CALHIV who received ART for 2-5 months and those who received ≥6 months were more likely to have a suppressed VL; (adj.PR =1.77; 95% CI: 1.23, 2.54) and (adj.PR=1.92; 95% CI: 1.37, 2.69) respectively. Those with a diagnosis of Tuberculosis were less likely to have a suppressed VL; (adj.PR=0.66; 95% CI: 0.61, 0.71). ART retention was better among the ≥6 months and 2-5 months dispensation i.e., 44.4% vs 50.65 vs 7.91%. Conclusions: CALHIV receiving multi-month ART including 6 months refills are more likely to achieve VL suppression. Early diagnosis and treatment of TB among CALHIV is critical in achieving VL suppression during multi-month dispensation General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 1 1 1 th 38 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=